Keywords: Impax, Generics, Welcol, Patent challenge, Daiichi Sankyo, Genzyme

Impax Labs sued by Daiichi Sankyo and Genzyme after challenging Welchol patent in USA

Article | 18 January 2010

US generic drugmaker Impax Laboratories confirmed that it has initiated a challenge to patents listed by Japanese drug firm Daiichi Sankyo in connection with its cholesterol-lowering product Welchol (colesevelam HCl) tablets, 625mg, including one that US biotech major Genzyme inherited when it acquired GelTex Pharmaceuticals in 2000. The patents are claimed to expire in 2014 and 2015.

Impax filed its Abbreviated New Drug Application containing a paragraph IV certification for a generic version of Welchol with the US Food & Drug Administration. Enjoying this artcle? To continue reading you need to login, take a FREE trial or subscribe.

30 day FREE trial

Sign up in less than 60 seconds! No payment needed.

Want to read the full article?
Take a 30 day FREE Trial

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in